Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.-Reference-Cited by-同舟云学术

Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:2009-2009
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Goldberg Sarah B.¹,Gettinger Scott N.¹,Mahajan Amit¹,Herbst Roy S.¹,Chiang Anne C.¹,Lilenbaum Rogerio¹,Jilaveanu Lucia¹,Rowen Elin¹,Gerrish Heather¹,Komlo Annette¹,Wei Wei²,Chiang Veronica¹,Kluger Harriet M.¹

Affiliation:

1. Yale School of Medicine, New Haven, CT;

2. Yale School of Public Health, New Haven, CT;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.2009

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patterns of brain metastases response to immunotherapy with pembrolizumab;Journal of Neuro-Oncology;2024-07-04

2. Treatment of Small Cell Lung Cancer patients with brain metastases shows promise with the combination therapy of Cardonilumab and Anlotinib;2024-01-29

3. Characterization of patients with brain metastases referred to palliative care;BMC Palliative Care;2024-01-11

4. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases;JCO Oncology Practice;2023-11

5. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic;Frontiers in Immunology;2023-10-09